



Topic Suggestions....Contact:
Pharmaceutical Services, Dept. of
Health and Community Services
P.O. Box 8700
St. John's, NL A1B 4J6
Tel: 729-6507; Fax 729-2851

Department of Health
and Community Services

Spring 2006

Behind the Scenes

Newfoundland and Labrador Prescription Drug Program (NLPDP)

Physician Special Authorization Notification

Physicians can now receive notification of special authorization approvals by fax. Avoid delay by postal service and receive notification the same day as pharmacies. Contact NLPDP at **753-3615** or **1-888-724-7760** for a form to request the change from mail to fax notification.

CHANGES TO THE NLPDP BENEFIT LISTING

New open benefits:

1. Addipak Sodium Chloride 0.9% Solution
2. DEY-Pak Sodium Chloride 0.9% Solution
3. Benztropine 1mg/mL Injection
4. PMS-Oxybutynin Syrup
5. Kaopectate Extra Strength Liquid (**Plan E only**)

Deletions:

1. Solu-Crom Ophthalmic
2. Co Pravastatin 10mg, 20mg and 40mg Tablets

Further benefit list deletions are listed in **Bulletin 63** which can be viewed or downloaded from <http://nlpdp.xwave.com/>

Drug Reviews Completed and Not Considered for Coverage:

The **Common Drug Review (CDR)** reviews new drugs and provides an evidence-based formulary listing recommendation, made by the [Canadian Expert Drug Advisory Committee \(CEDAC\)](#), on behalf of publicly-funded drug plans. The review for the following product was completed by the Common Drug Review and coverage was not recommended. As such, this product will not be considered for coverage under the NLPDP. CEDAC recommendations can be viewed at www.ccohta.ca

Ebixa

The **Atlantic Common Drug Review (ACDR)** is a regional review process that provides evidence-based recommendations for coverage of new indications and line extensions for existing medications. Drug evaluation summaries are prepared by independent reviewers based on the manufacturer's drug submission and a systematic literature search. The drug evaluation summary is presented to the Atlantic Expert Advisory Committee who recommends the place in therapy. It is then up to each individual province to make a decision as to the coverage status. The reviews for the following products were completed by the ACDR and coverage was not recommended. As such, these products will not be considered for coverage under the NLPDP.

Paxil CR

Diamicron MR

Avandamet

Amaryl

Zaditor Ophthalmic Drops

Nexium

Pennsaid

The Newfoundland and Labrador Interchangeable Formulary:

New Categories:

1. Alendronate 40mg and 70mg Tablets
2. Cilazapril Monohydrate 1mg, 2.5mg and 5mg Tablets
3. Medroxyprogesterone Acetate 100mg Tablets
4. Topiramate 25mg, 100mg and 200mg Tablets
5. Gabapentin 600mg and 800mg Tablets
6. Ranitidine Oral Solution 15mg/ml
7. Estradiol Transdermal Patch 50ug, 75ug and 100ug
8. Hydrocortisone Acetate 10mg/Zinc Sulfate 10mg Rectal Suppository
9. Hydrocortisone Acetate 10mg/Pramoxine HCL 20mg/Zinc Sulfate 10mg Rectal Suppository

Additions:

Novo-Warfarin 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 10mg Tablets

Other additions are listed in **Bulletin 57** which can be viewed or downloaded from <http://nlpdp.xwave.com/>

Deletions:

Co Pravastatin 10mg, 20mg and 40mg Tablets